The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL).
Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer.
In this study, doctors from Europe evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting.
|The incidence of febrile neutropenia was 2%.|
|New England Journal of Medicine|
The team randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with oxaliplatin for 6 months.
They measured the rate of disease-free survival.
The doctors found that after a median follow-up of 37.9 months, 21% of patients FL plus oxaliplatin group had had a cancer-related event. This compared with 26% of patients in the FL group.
They found that disease-free survival at 3 years was 78% in the FL plus oxaliplatin group and 73% in the FL only group.
However, in the FL plus oxaliplatin group the incidence of febrile neutropenia was 2%, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12% during treatment.
Dr Thierry André and colleagues concluded, “Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer“.